January 2020

Interviews with researchers and opinion leaders that took place during the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, Florida, December 7-10, 2019.

Results for Truxima, recently launched in the United States, and complement inhibitors were presented at the 61st American Society of Hematology Annual Meeting and Exposition.

The abstract presented by Kwanza Price, MPH, of Jazz Pharmaceuticals, gathered data from August 1, 2017, and February 28, 2019, capturing the first 19 months of claims data after the biotech received FDA approval for its fixed-dose therapy for 2 types of poor-prognosis acute myeloid leukemia.

Symptom burden, functional ability, and quality of life are necessary considerations when treating hematologic malignancies in older patients.

Reviews of apixaban in active cancer, Medicare costs after CAR T-cell therapy, and the need for financial assistance for novel therapies.

Results from clinical trials presented at the 2019 American Society of Hematology Annual Meeting and Exposition in Orlando, Florida.

A pair of interviews on investigational therapies whose sponsors reported updates at the 61st American Society of Hematology Annual Meeting and Exposition: UCART19 from Servier and a revamped anti-BCMA therapy ide-cel from bluebird bio.

Coverage from the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, Florida, featured results for allogeneic or "off the shelf" CAR T-cell treatments and bispecific antibodies.